NCT04837339 Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
| NCT ID | NCT04837339 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hopital Foch |
| Condition | Lung Transplant Rejection |
| Study Type | INTERVENTIONAL |
| Enrollment | 900 participants |
| Start Date | 2022-03-17 |
| Primary Completion | 2037-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 900 participants in total. It began in 2022-03-17 with a primary completion date of 2037-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation. Each dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.
Eligibility Criteria
Inclusion Criteria: * Men or women over 15 years of age * Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant * Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has/have signed the informed consent. * Be affiliated with a Health Insurance plan. Exclusion Criteria: * Pregnant, parturient and/or lactating woman * Hemoglobin level less than or equal to 8g/dl * Persons of full age who are subject to a legal protection measure or who are unable to express their consent * Persons under the protection of justice * Not being able to follow the study requirements for geographical, social or psychological reasons * Patient refusal.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04837339 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, studying Lung Transplant Rejection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04837339 currently recruiting?
Yes, NCT04837339 is actively recruiting participants. Contact the research team at a.roux@hopital-foch.com for enrollment information.
Where is the NCT04837339 trial being conducted?
This trial is being conducted at Suresnes, France.
Who is sponsoring the NCT04837339 clinical trial?
NCT04837339 is sponsored by Hopital Foch. The trial plans to enroll 900 participants.